glp-1 agonist pharmacology Frontiers Discovery of GLP-1–Based Drugs for

Among these potential key players, Roche continues to stand out with multiple obesity candidates within its pipeline, all in phase II trials (as of November 2025), and it is expected to enter the market in 2029 or later

Novo and Lilly both have faced competition from telehealth companies that still sell compounded versions of the anti-obesity drugs, often selling them for less

23 Provider bias, lack of culturally competent care, and limited access to specialists contribute to these disparities

However small human studies suggest that yerba mate or green mate (the same active compound) can be helpful for fat loss and appetite reduction

Novo also agreed at the time to sell oral Wegovy for $150 for the initial dosesa promise it made good on when the pill launched last month

A consistent pattern emerges in phenotypes with a high metabolic burden, such as obesity and IGT or pre-diabetes, improvements in fasting glucose, OGTT curves, and HbA1c are more pronounced, with some subjects even reverting from IGT to normoglycemia